Unknown

Dataset Information

0

Targeting development of incretin-producing cells increases insulin secretion.


ABSTRACT: Glucagon-like peptide-1-based (GLP-1-based) therapies improve glycemic control in patients with type 2 diabetes. While these agents augment insulin secretion, they do not mimic the physiological meal-related rise and fall of GLP-1 concentrations. Here, we tested the hypothesis that increasing the number of intestinal L cells, which produce GLP-1, is an alternative strategy to augment insulin responses and improve glucose tolerance. Blocking the NOTCH signaling pathway with the ?-secretase inhibitor dibenzazepine increased the number of L cells in intestinal organoid-based mouse and human culture systems and augmented glucose-stimulated GLP-1 secretion. In a high-fat diet-fed mouse model of impaired glucose tolerance and type 2 diabetes, dibenzazepine administration increased L cell numbers in the intestine, improved the early insulin response to glucose, and restored glucose tolerance. Dibenzazepine also increased K cell numbers, resulting in increased gastric inhibitory polypeptide (GIP) secretion. Using a GLP-1 receptor antagonist, we determined that the insulinotropic effect of dibenzazepine was mediated through an increase in GLP-1 signaling. Together, our data indicate that modulation of the development of incretin-producing cells in the intestine has potential as a therapeutic strategy to improve glycemic control.

SUBMITTER: Petersen N 

PROVIDER: S-EPMC4382243 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting development of incretin-producing cells increases insulin secretion.

Petersen Natalia N   Reimann Frank F   van Es Johan H JH   van den Berg Bernard M BM   Kroone Chantal C   Pais Ramona R   Jansen Erik E   Clevers Hans H   Gribble Fiona M FM   de Koning Eelco J P EJ  

The Journal of clinical investigation 20141215 1


Glucagon-like peptide-1-based (GLP-1-based) therapies improve glycemic control in patients with type 2 diabetes. While these agents augment insulin secretion, they do not mimic the physiological meal-related rise and fall of GLP-1 concentrations. Here, we tested the hypothesis that increasing the number of intestinal L cells, which produce GLP-1, is an alternative strategy to augment insulin responses and improve glucose tolerance. Blocking the NOTCH signaling pathway with the γ-secretase inhibi  ...[more]

Similar Datasets

| S-EPMC4736448 | biostudies-literature
| S-EPMC3053597 | biostudies-literature
| S-EPMC3773820 | biostudies-literature
| S-EPMC4012477 | biostudies-literature
| S-EPMC6393347 | biostudies-literature
| S-EPMC4920590 | biostudies-literature
| S-EPMC5850988 | biostudies-literature
| S-EPMC3709998 | biostudies-literature
| S-EPMC4854503 | biostudies-other
| S-EPMC2699873 | biostudies-literature